Stories
MedPlus CEO Says Cancer Drug Margin Cap Has Minimal Impact, Urges Focus on Quality
- •MedPlus Health Services CEO Gangadi Madhukar Reddy stated that the government's 30 percent trade margin cap on non-scheduled anti-cancer drugs will have a negligible impact on the company.
- •Oncology medicines account for less than 0.1 to 0.2 percent of the pharmacy retailer's overall sales.
- •Reddy expressed skepticism about margin caps, arguing that allowing market forces and competition is a better approach to naturally driving down prices.
- •The CEO emphasized that India's primary focus should shift from price to drug quality, warning about the threat of counterfeit and substandard medicines entering the supply chain.
Key Questions Answered
According to MedPlus CEO Gangadi Madhukar Reddy, the government's decision to cap trade margins on non-scheduled anti-cancer drugs at 30% will have a negligible impact on the company. Oncology medicines account for a minuscule fraction of MedPlus's overall sales, representing less than 0.1% to 0.2% of its revenue.
The government's cap on trade margins for non-scheduled anti-cancer drugs at 30% of the maximum retail price is expected to reduce prices by up to 70%. This regulatory move aims to address excessive mark-ups and generate an estimated annual savings of Rs 2,500 crore for cancer patients.
MedPlus CEO Gangadi Madhukar Reddy explained that significant expenses are involved in manufacturing and distributing generic medicines to doctors and patients. Additionally, the limited patient pool for cancer treatments requires fewer drugs to be produced, necessitating higher profit margins to sustain overall operations.
